Defence Therapeutics (XCNQ:DTC) Change In Payables And Accrued Expense : C$0.58 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Change In Payables And Accrued Expense?

Defence Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was C$1.06 Mil. It means Defence Therapeutics's Accounts Payable & Accrued Expense increased by C$1.06 Mil from Sep. 2023 to Dec. 2023 .

Defence Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2022 was C$0.99 Mil. It means Defence Therapeutics's Accounts Payable & Accrued Expense increased by C$0.99 Mil from Jun. 2021 to Jun. 2022 .

Defence Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Defence Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Change In Payables And Accrued Expense Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Change In Payables And Accrued Expense

0.04

0.07

0.99

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial										0.13	-0.41	-0.65	0.17	1.06

Defence Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.58 Mil.

Defence Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.

Executives

Sarkis Meterissian

Director